Detall de la convocatòria

Expressió d'interès - Expression of interest

Característiques

Característica
Objectiu de la convocatòria
The Technology Impact Award provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists.
Característiques principals
These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact::
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: cbarnwell@researchmar.net Ext.: 1670
Marta López: mlopez4@researchmar.net Ext.: 1576
Convocatòria (URL)
https://www.cancerresearch.org/scientists/fellowships-grants/technology-impact-award
Requisits
  • Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. If not, documentation from their institution must accompany the Letter of Intent indicating they will hold the position of assistant professor (or higher rank) by the time of award activation.
  • The grant will be awarded to a scientist who describes an extraordinarily novel, yet practical research plan that is creative and technically sophisticated.
  • Joint submissions from collaborators will also be considered. (The collaborators will share the award.) Each collaborator must meet the eligibility criteria.
  • Selected projects that meet their 12 and 24 month milestones may be eligible for follow-on funding that will enable the established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide.
    • Dotació
    $200.000
    Durada
    12-24 months
    Documentació
    Letters of intent must be submitted electronically at: https://cri.us-1.smartsimple.com/s_Login.jsp
    Supporting documentation:
  • Abstract of research in nontechnical English explaining the significance of the new technology platform and its impact on the field of cancer immunotherapy. Not to exceed 250 words.
  • An initial research concept (succinct description of the proposed research plan with specific aims and timelines, description of the how the proposed technology platform has the potential to transform the field of cancer immunotherapy), not to exceed 3 pages.
  • Brief description of your current research.
  • Curriculum vitae and bibliography (limit bibliography to past 5 years or publications relevant to proposed research).
  • If applicable, curriculum vitae for all group members, as well as a description of each member's research focus.
    • AVÍS IMPORTANT
    This grant follows as a two-stage:
  • Letter of Intent: Deadline 15 November 2024
  • Invited Application: Deadline 15 March 2025

    • Arxius

    Arxiu
    Revenue-Sharing-Agreement.pdf
    CRI-Invention-Disclosure-Form-1.pdf
    TECH_Terms_2022-10_-_web.pdf
    TECH-LOI-Cover-Sheet.pdf
    Annual-Invention-Update-Form-1.pdf